TENAX THERAPEUTICS, INC. Net Income Loss

• TENAX THERAPEUTICS, INC. showed a decrease of -198.8% in Net Income Loss from 2024 to 2025.
• This data is from TENAX THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), TENAX THERAPEUTICS, INC.'s Net Income Loss has declined by 603.4%.
• Historical annual values: Fiscal year 2025: -$52.60 million | Fiscal year 2024: -$17.60 million | Fiscal year 2023: -$7.71 million | Fiscal year 2022: $11.05 million | Fiscal year 2021: -$32.47 million | Fiscal year 2020: -$9.85 million | Fiscal year 2019: -$8.39 million | Fiscal year 2018: -$14.14 million | Fiscal year 2017: -$8.84 million | Fiscal year 2016: -$43.92 million | Fiscal year 2015: -$14.08 million | Fiscal year 2014: -$19.54 million | Fiscal year 2013: -$9.42 million | Fiscal year 2012: -$15.71 million | Fiscal year 2011: $10.45 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026